

Special Issue

Plastic and Reconstructive Surgery in Personalized Medicine: 2nd Edition

Message from the Guest Editors

The tremendous success of the Special Issue “Plastic and Reconstructive Surgery in Personalized Medicine” and multiple requests to continue this series revealed to us the need for further research in this new field of reconstructive surgery and inspired us to continue the series. This Special Issue of the Journal of Personalized Medicine Part II focuses on the following topics: Individualized microsurgery and reconstructive surgery; Perioperative flap imaging; Customized perforator flaps; Monitoring flap perfusion; Tailored tissue engineering for reconstruction; Biofabrication applications in personalized plastic and reconstructive surgery. Please submit your article with your latest achievements in these fields to the journal. We look forward to receiving your contributions to this journal.

Guest Editors


Prof. Dr. Raymund E. Horch

Dr. Aijia Cai

Prof. Dr. Andreas Arkudas

Deadline for manuscript submissions

10 July 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/182472

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).